Brief: Celsion Reports DSMB Unanimous Recommendation To Continue Dosing Patients In Phase II Portion Of Study With Gen-1 In Advanced Ovarian Cancer

Imunon

17/02/2022 13:54

Feb 17 (Reuters) - Celsion Corp  CLSN.O :
    * CELSION REPORTS DATA SAFETY MONITORING BOARD UNANIMOUS
RECOMMENDATION TO CONTINUE DOSING PATIENTS IN PHASE II PORTION
OF OVATION 2 STUDY WITH GEN-1 IN ADVANCED OVARIAN CANCER
    * CELSION CORP - OVATION 2 STUDY IS OVER 75% ENROLLED; FULL
ENROLLMENT EXPECTED BY MID-2022

Source text for Eikon:  ID:nGNXb977Zr 
Further company coverage:  CLSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))